IDEAYA Biosciences, Inc. to Post Q1 2025 Earnings of ($0.72) Per Share, Wedbush Forecasts (NASDAQ:IDYA)

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Stock analysts at Wedbush issued their Q1 2025 earnings estimates for shares of IDEAYA Biosciences in a report issued on Tuesday, May 7th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($0.72) for the quarter. Wedbush currently has a “Outperform” rating and a $52.00 price target on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.26) per share. Wedbush also issued estimates for IDEAYA Biosciences’ Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.78) EPS and FY2028 earnings at $4.10 EPS.

Other equities research analysts have also issued research reports about the stock. Citigroup increased their price objective on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, March 21st. Royal Bank of Canada increased their price objective on shares of IDEAYA Biosciences from $43.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, February 21st. BTIG Research assumed coverage on shares of IDEAYA Biosciences in a report on Friday, March 8th. They set a “buy” rating and a $55.00 price objective on the stock. JPMorgan Chase & Co. lifted their price target on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Finally, Leerink Partnrs restated an “outperform” rating on shares of IDEAYA Biosciences in a report on Friday, February 23rd. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, IDEAYA Biosciences has an average rating of “Buy” and a consensus price target of $47.50.

IDEAYA Biosciences Stock Down 3.1 %

Shares of NASDAQ:IDYA opened at $41.41 on Thursday. IDEAYA Biosciences has a 12 month low of $19.01 and a 12 month high of $47.74. The company’s 50-day moving average price is $42.63 and its two-hundred day moving average price is $38.38. The firm has a market cap of $3.10 billion, a P/E ratio of -21.02 and a beta of 0.83.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 23.00% and a negative net margin of 483.05%. The business’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.49) EPS.

Insider Transactions at IDEAYA Biosciences

In other news, insider Briseno Andres Ruiz sold 2,000 shares of IDEAYA Biosciences stock in a transaction on Friday, February 9th. The shares were sold at an average price of $46.02, for a total transaction of $92,040.00. Following the transaction, the insider now directly owns 24,531 shares of the company’s stock, valued at $1,128,916.62. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Briseno Andres Ruiz sold 2,000 shares of IDEAYA Biosciences stock in a transaction on Friday, February 9th. The shares were sold at an average price of $46.02, for a total transaction of $92,040.00. Following the transaction, the insider now directly owns 24,531 shares of the company’s stock, valued at $1,128,916.62. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Yujiro S. Hata sold 23,557 shares of IDEAYA Biosciences stock in a transaction on Friday, February 9th. The stock was sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the transaction, the chief executive officer now directly owns 677,887 shares in the company, valued at $30,870,973.98. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Capital Research Global Investors lifted its position in IDEAYA Biosciences by 43.6% in the 4th quarter. Capital Research Global Investors now owns 1,976,870 shares of the company’s stock valued at $70,337,000 after acquiring an additional 600,000 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in IDEAYA Biosciences by 17.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,566,278 shares of the company’s stock valued at $126,889,000 after acquiring an additional 535,909 shares in the last quarter. Fisher Asset Management LLC lifted its position in IDEAYA Biosciences by 1,611.9% in the 4th quarter. Fisher Asset Management LLC now owns 539,676 shares of the company’s stock valued at $19,202,000 after acquiring an additional 508,151 shares in the last quarter. Vanguard Group Inc. lifted its position in IDEAYA Biosciences by 17.0% in the 4th quarter. Vanguard Group Inc. now owns 3,475,772 shares of the company’s stock valued at $123,668,000 after acquiring an additional 504,275 shares in the last quarter. Finally, Federated Hermes Inc. lifted its position in IDEAYA Biosciences by 14.8% in the 4th quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company’s stock valued at $138,185,000 after acquiring an additional 500,046 shares in the last quarter. 98.29% of the stock is owned by institutional investors.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.